Noriyuki Nishimura
Overview
Explore the profile of Noriyuki Nishimura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
110
Citations
4584
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Miura T, Watanabe A, Miyake M, Suga S, Miyoshi M, Miyashita K, et al.
Med Mol Morphol
. 2025 Mar;
PMID: 40063301
Pancreatic cancer is a malignant tumor that metastasizes to distant organs, such as the liver and lungs from an early stage. Few animal models can reproduce early metastasis. In addition,...
2.
Kushida Y, Oguma Y, Abe K, Deguchi T, Barbera F, Nishimura N, et al.
Cell Mol Life Sci
. 2024 Jul;
81(1):297.
PMID: 38992309
Muse cells, identified as cells positive for the pluripotent surface marker SSEA-3, are pluripotent-like endogenous stem cells located in the bone marrow (BM), peripheral blood, and organ connective tissues. The...
3.
Ishida H, Imamura T, Kobayashi R, Hashii Y, Deguchi T, Miyamura T, et al.
Cancer Med
. 2024 Jun;
13(12):e7246.
PMID: 38888368
Background: Asparaginase is essential for treating T-cell acute lymphoblastic leukemia (T-ALL). Despite the ongoing debate on whether T-ALL and T-cell lymphoblastic lymphoma (T-LBL) are the same disease entity or two...
4.
Nakatani N, Win K, Mon C, Fujikawa T, Uemura S, Saito A, et al.
Biology (Basel)
. 2024 May;
13(5).
PMID: 38785826
Non-high-risk (non-HR) neuroblastoma (NB) patients have excellent outcomes, with more than a 90% survival rate, whereas HR NB patients expect less than a 50% survival rate. Metastatic disease is the...
5.
Win K, Kushida Y, Yamana K, Iwatani S, Yoshida M, Nino N, et al.
Stem Cell Res Ther
. 2024 May;
15(1):147.
PMID: 38773627
Background: Bleomycin (BLM)-induced lung injury is characterized by mixed histopathologic changes with inflammation and fibrosis, such as observed in human patients with bronchopulmonary dysplasia, idiopathic pulmonary fibrosis, and chronic obstructive...
6.
Niba E, Awano H, Nishimura N, Koide H, Matsuo M, Shinohara M
Am J Physiol Cell Physiol
. 2024 Apr;
327(1):C34-C47.
PMID: 38646787
The dystrophin gene () is recognized for its significance in Duchenne muscular dystrophy (DMD), a lethal and progressive skeletal muscle disease. Some patients with DMD and model mice with muscular...
7.
Nishimura N, Ishida T, Yokota I, Matsumoto K, Shichino H, Fujisaki H, et al.
Biology (Basel)
. 2023 Oct;
12(10).
PMID: 37887060
High-risk neuroblastoma (HR-NB) patients remain far from obtaining optimal outcomes, with more than 50% relapse/regrowth rate despite current intensive multimodal therapy. This originated from the activation/proliferation of chemoresistant minimal residual...
8.
Inoue S, Win K, Mon C, Fujikawa T, Hyodo S, Uemura S, et al.
Oncol Lett
. 2023 Aug;
26(3):369.
PMID: 37559575
More than half of patients with high-risk neuroblastoma (HR-NB) experience relapse/regrowth due to the activation of chemoresistant minimal residual disease (MRD). MRD in patients with HR-NB can be evaluated by...
9.
Nino N, Ishida T, Nakatani N, Lin K, Win K, Mon C, et al.
Heliyon
. 2022 Oct;
8(10):e10978.
PMID: 36276741
More than half of high-risk neuroblastoma (NB) patients have experienced relapse due to the activation of chemoresistant minimal residual disease (MRD) even though they are treated by high-dose chemotherapy with...
10.
Tomioka K, Nishiyama M, Nagase H, Ishida Y, Tanaka T, Tokumoto S, et al.
Brain Dev
. 2022 Sep;
44(10):771-772.
PMID: 36055910
No abstract available.